Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Tenaya Therapeutics (TNYA) Stock Price & Analysis
396 Followers
TNYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.66 - $7.01
Previous Close$3.51
Volume271.15K
Average Volume (3M)360.84K
Market Cap
$275.60M
Enterprise Value$164.71M
Total Cash (Recent Filing)$122.25M
Total Debt (Recent Filing)$11.37M
Price to Earnings (P/E)―
Beta2.92
Next Earnings
Aug 07, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding78,517,534
10 Day Avg. Volume301,815
30 Day Avg. Volume360,840
Standard Deviation0.31
R-Squared0.18
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$19.17Price Target Upside444.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tenaya Therapeutics News
PremiumCompany Announcements
Jin-Long Chen Resigns Amicably from Tenaya Therapeutics Board
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnticipation growing for first TN-201 data.
Financial StabilityTenaya’s recent $50M equity raise extends runway into H2 2025 and provides valuable buffer space.
Regulatory ProgressPositive commentary from the FDA and recent regulatory precedent give optimism on a potential accelerated registrational pathway.
Bears Say
Corporate ActionsTNYA announced a cost reduction plan including a 22% reduction in workforce expected to be complete in 2Q24.
EarningsTNYA reported a first quarter net loss of $32.2M.
Financial PerformanceTNYA's 1Q24 earnings report was uneventful, with pipeline updates largely on track.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $1.66 and its highest was $7.01 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Currently, no data Available
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on May 14, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.022.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -$0.39.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 78,517,530 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went down -3.409%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Among the largest hedge funds holding Tenaya Therapeutics’s share is RA Capital Management. It holds Tenaya Therapeutics’s shares valued at 30M.
---
Tenaya Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.17 (444.60% Upside)
$19.17 (444.60% Upside)
Hedge Fund Trend
Increased
By 303.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.43%
12-Months-Change
Fundamentals
Return on Equity
-66.69%
Trailing 12-Months
Asset Growth
-24.64%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
---
TNYA Stock 12 Month Forecast
Average Price Target
$19.17
▲(444.60% Upside)
Technical Analysis
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+22.39%
reiterated a buy rating 14 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +22.39% per trade.
---